At-Home Subcutaneous Furosemide Reduces Heart Failure Hospitalizations
A new study shows patients with severe heart failure at imminent risk of hospitalization can be effectively treated at home with subcutaneous furosemide. Results were presented at the HFSA Annual Scientific Meeting.
SQ Innovation has released interim results from a study evaluating the efficacy of Lasix ONYU, a novel subcutaneous formulation of furosemide, for patients experiencing worsening heart failure. The study involved 21 patients at imminent risk of hospital admission who received treatment at home on the day of presentation. Of these, 86% achieved adequate decongestion without requiring hospitalization.
The Gator SCALES-WHF study, conducted at the University of Florida, gathered data from patients who had not responded sufficiently to oral diuretics. The aim was to assess whether home-based treatment could achieve effective fluid removal and avoid hospital stays.
Three patients were admitted to the hospital within a 30-day follow-up period for additional treatment. Issues related to user, device, or safety were minimal, and no patient discontinued treatment due to adverse events. The study findings were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Phoenix.
Fluid overload from heart failure is a leading cause of hospitalization for individuals over 65. This new home treatment approach is expected to reduce hospital burden and improve patient quality of life.